• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

NIH Awards $70M to Launch Alzheimer’s Clinical Trials Consortium

by Jasmine Pennic 12/12/2017 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Alzheimer's Clinical Trials Consortium

The National Institutes of Health (NIH) announced it is expected to award up to $70 million over five years to three physician-scientists to launch the Alzheimer’s Clinical Trials Consortium (ACTC). The consortium will create a network of 35 Alzheimer’s disease trial sites across the country with the goal of finding new ways to treat or prevent Alzheimer’s. Reisa Sperling, MD, director of the Center for Alzheimer Research and Treatment at Brigham and Women’s Hospital, will collaborate with colleagues at the Mayo Clinic and the Keck School of Medicine at the University of Southern California (USC) to accelerate clinical trials for Alzheimer’s disease and related dementias.

Alzheimer’s Clinical Trials Consortium (ACTC) Overview

The ACTC will be led jointly by research teams across the country including a team from Brigham and Women’s Hospital and Massachusetts General Hospital. Other leaders include Paul Stephen Aisen, MD, from the Alzheimer Therapeutic Research Institute, at University of Southern California, Los Angeles, and Ronald C. Petersen, MD, PhD, the Mayo Clinic, Rochester, Minnesota with scientific input from the National Institute on Aging (NIA) at NIH — the federal leader in Alzheimer’s research.

The consortium’s diverse team and improved infrastructure will alleviate some of the challenges involved in conducting clinical trials, including the expense of recruitment and site activation. Several other leading researchers at BWH, including Dennis Selkoe, MD, Gad Marshall, MD, Dominic Walsh, PhD, and Dorene Rentz, PsyD, will work on ACTC efforts to implement more sensitive biomarkers and cognitive tests in early intervention trials. The consortium will offer shared support services, enabling researchers to design better clinical trials, manage and analyze large amounts of data, and recruit participants from diverse backgrounds. The group will also share data, software, instruments and biologic samples such as blood, tissue and cerebrospinal fluid.

The ACTC will also help researchers engage in new collaborations to test promising therapies and prevention strategies. Researchers at the Brigham and their colleagues are leading efforts to find ways to intervene as early as possible, before the first signs and symptoms of Alzheimer’s appear when some treatments are expected to be most effective. But prevention trials – such as the A4 Study led by Sperling and her collaborators – can require screening thousands of volunteers to identify eligible participants, which can be time- and resource-consuming. The ACTC aims to offer the infrastructure, shared resources and expertise to help surmount these hurdles.

“We must overhaul our current recruitment strategies for clinical trials, particularly to improve the diversity of our study participants and to reach people who do not yet have symptoms of Alzheimer’s disease for inclusion in future prevention trials,” said Sperling, who serves as the principal investigator of the ACTC at both BWH and Massachusetts General Hospital and is also professor of Neurology at Harvard Medical School. “The new ACTC presents a terrific opportunity to innovate in recruitment, cognitive assessments and neuroimaging for the next generation of Alzheimer’s trials.”

Image Credit via creative commons: Albert Einstein College of Medicine

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Alzheimer's Clinical Trials Consortium, Clinical Trials, National Institutes of Health (NIH)

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Knowledge Hub

How AI Helps Health Systems Improve the Quality of Care for Patients with Chronic Conditions

How AI Helps Health Systems Improve the Quality of Care for Patients with Chronic Conditions

10 Critical KPIs Every Successful Healthcare Organization is Implementing10 Critical KPIs Every Successful Healthcare Organization is Implementing

Trending

Why The Evolution of Tech Will be Based on APIs

Why The Evolution of Tech Will be Based on APIs

Podimetrics CMO Talks Supporting Patients Living with SDoH Challenges

Podimetrics Director Talks Supporting Patients Living with SDoH Challenges

: Does Alzheimer’s Cure Matter if We Don't Fix the Economic Infrastructure of the Disease?

Does Alzheimer’s Cure Matter if We Don’t Fix the Economic Infrastructure of the Disease?

Recent Digital Health Partnerships

Roundups: 15 Recent Digital Health Strategic Partnerships

Recent Digital Health Executive Hires & Board Appointments

Digital Health Executive Hires: Practice Better Appoints CEO, HHAeXchange, Intelerad, Tegria, Others

M&A: Florence Acquires Virtual Care Solution Zipnosis

M&A: Florence Acquires Virtual Care Solution Zipnosis

Adopting Value-Based Care Models for Autism Care Is Imperative

Why Adopting Value-Based Care Models for Autism Care Is Imperative

UNC Health to Pilot Epic, Microsoft’s Generative AI Tool

UNC Health to Pilot Epic, Microsoft’s Generative AI Tool

Vanderbilt University Medical Center Taps Philips Reduce Carbon Footprint

Vanderbilt University Medical Center Taps Philips to Reduce Carbon Footprint

Denials Management Named Most Time-Consuming Task in RCM

Denials Management Named Most Time-Consuming Task in RCM

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |